1. Swann, J. B., and M. J. Smyth. 2007. Immune surveillance of tumors. J. Clin. Invest. 117: 1137‒1146.
2. Grivennikov, S. I., F. R. Greten, and M. Karin. 2010. Immunity, inflammation, and cancer. Cell 140: 883‒899.
3. Nickoloff, B. J., Y. Ben-Neriah, and E. Pikarsky. 2005. Inflammation and cancer: is the link as simple as we think? J. Invest. Dermatol. 124: x‒xiv.
4. Shibuya, A., D. Campbell, C. Hannum, H. Yssel, K. Franz-Bacon, T. McClanahan, T. Kitamura, J. Nicholl, G. R. Sutherland, L. L. Lanier, and J. H. Phillips. 1996. DNAM-1, a novel adhesion molecule involved in the cytolytic function of T lymphocytes. Immunity 4: 573‒581.
5. Iguchi-Manaka, A., H. Kai, Y. Yamashita, K. Shibata, S. Tahara-Hanaoka, S.- I. Honda, T. Yasui, H. Kikutani, K. Shibuya, and A. Shibuya. 2008. Accelerated tumor growth in mice deficient in DNAM-1 receptor. J. Exp. Med. 205: 2959‒2964.
6. Zhang, R., H. Zeng, Y. Zhang, K. Chen, C. Zhang, C. Song, L. Fang, Z. Xu, K. Yang, B. Jin, Q. Wang, and L. Chen. 2016. CD226 ligation protects against EAE by promoting IL-10 expression via regulation of CD4+ T cell differentiation. Oncotarget 7: 19251‒19264.
7. Shapiro, M. R., W.-I. Yeh, J. R. Longfield, J. Gallagher, C. M. Infante, S. Wellford, A. L. Posgai, M. A. Atkinson, M. Campbell-Thompson, S. M. Lieberman, D. V. Serreze, A. M. Geurts, Y.-G. Chen, and T. M. Brusko. 2020. CD226 Deletion Reduces Type 1 Diabetes in the NOD Mouse by Impairing Thymocyte Development and Peripheral T Cell Activation. Front. Immunol. 11: 2180.
8. Wang, N., P. Chen, Y. Song, Y. Shen, J. Li, X. Li, L. Fang, and L. Chen. 2021. CD226 deficiency attenuates the homeostasis and suppressive capacity of Tr1 cells. Mol. Immunol. .
9. Chauvin, J.-M., and H. M. Zarour. 2020. TIGIT in cancer immunotherapy. J Immunother Cancer 8: e000957.
10. Alteber, Z., M. F. Kotturi, S. Whelan, S. Ganguly, E. Weyl, D. M. Pardoll, J. Hunter, and E. Ophir. 2021. Therapeutic Targeting of Checkpoint Receptors within the DNAM1 Axis. Cancer Discov. 11: 1040‒1051.
11. Greten, F. R., and S. I. Grivennikov. 2019. Inflammation and Cancer: Triggers, Mechanisms, and Consequences. Immunity 51: 27‒41.
12. Abel, E. L., J. M. Angel, K. Kiguchi, and J. DiGiovanni. 2009. Multi-stage chemical carcinogenesis in mouse skin: fundamentals and applications. Nat. Protoc. 4: 1350‒1362.
13. De Robertis, M., E. Massi, M. L. Poeta, S. Carotti, S. Morini, L. Cecchetelli, E. Signori, and V. M. Fazio. 2011. The AOM/DSS murine model for the study of colon carcinogenesis: From pathways to diagnosis and therapy studies. J. Carcinog. 10: 9.
14. Suganuma, M., S. Okabe, M. W. Marino, A. Sakai, E. Sueoka, and H. Fujiki. 1999. Essential role of tumor necrosis factor alpha (TNF-alpha) in tumor promotion as revealed by TNF-alpha-deficient mice. Cancer Res. 59: 4516‒ 4518.
15. Wang, L., T. Yi, W. Zhang, D. M. Pardoll, and H. Yu. 2010. IL-17 enhances tumor development in carcinogen-induced skin cancer. Cancer Res. 70: 10112‒10120.
16. Ortiz, M. L., V. Kumar, A. Martner, S. Mony, L. Donthireddy, T. Condamine, J. Seykora, S. C. Knight, G. Malietzis, G. H. Lee, M. Moorghen, B. Lenox, N. Luetteke, E. Celis, and D. Gabrilovich. 2015. Immature myeloid cells directly contribute to skin tumor development by recruiting IL-17-producing CD4+ T cells. J. Exp. Med. 212: 351‒367.
17. Sharma, S. D., S. M. Meeran, N. Katiyar, G. B. Tisdale, N. Yusuf, H. Xu, C. A. Elmets, and S. K. Katiyar. 2009. IL-12 deficiency suppresses 12-O- tetradecanoylphorbol-13-acetate-induced skin tumor development in 7,12- dimethylbenz(a)anthracene-initiated mouse skin through inhibition of inflammation. Carcinogenesis 30: 1970‒1977.
18. Reiners, J. J., Jr, T. Rupp, A. Colby, A. R. Cantu, and A. Pavone. 1989. Tumor copromoting activity of gamma-interferon in the murine skin multistage carcinogenesis model. Cancer Res. 49: 1202‒1206.
19. Xiao, M., C. Wang, J. Zhang, Z. Li, X. Zhao, and Z. Qin. 2009. IFNγ Promotes Papilloma Development by Up-regulating Th17-Associated Inflammation. Cancer Res. 69: 2010‒2017.
20. Girardi, M., D. E. Oppenheim, C. R. Steele, J. M. Lewis, E. Glusac, R. Filler, P. Hobby, B. Sutton, R. E. Tigelaar, and A. C. Hayday. 2001. Regulation of Cutaneous Malignancy by γδ T Cells. Science 294: 605‒609.
21. Winkler, A. E., J. J. Brotman, M. E. Pittman, N. P. Judd, J. S. Lewis, R. D. Schreiber, and R. Uppaluri. 2011. CXCR3 Enhances a T-Cell‒Dependent Epidermal Proliferative Response and Promotes Skin Tumorigenesis. Cancer Res. 71: 5707‒5716.
22. Yusuf, N., T. H. Nasti, S. K. Katiyar, M. K. Jacobs, M. D. Seibert, A. C. Ginsburg, L. Timares, H. Xu, and C. A. Elmets. 2008. Antagonistic roles of CD4+ and CD8+ T-cells in 7,12-dimethylbenz(a)anthracene cutaneous carcinogenesis. Cancer Res. 68: 3924‒3930.
23. Zhang, J., L. Chen, M. Xiao, C. Wang, and Z. Qin. 2011. FSP1+ fibroblasts promote skin carcinogenesis by maintaining MCP-1-mediated macrophage infiltration and chronic inflammation. Am. J. Pathol. 178: 382‒390.
24. Kojima, H., H. Kanada, S. Shimizu, E. Kasama, K. Shibuya, H. Nakauchi, T. Nagasawa, and A. Shibuya. 2003. CD226 mediates platelet and megakaryocytic cell adhesion to vascular endothelial cells. J. Biol. Chem. 278: 36748‒36753.
25. Shibuya, A., S. Tahara-Hanaoka, and K. Shibuya. 2005. DNAM-1 (CD226): A Two-Sword Fencer for Innate and Adaptive Immunity. Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents 4: 53‒58.
26. Tahara‐Hanaoka, S., K. Shibuya, Y. Onoda, H. Zhang, S. Yamazaki, A. Miyamoto, S. Honda, L. L. Lanier, and A. Shibuya. 2004. Functional characterization of DNAM‐1 (CD226) interaction with its ligands PVR (CD155) and nectin‐2 (PRR‐2/CD112). Int. Immunol. 16: 533‒538.
27. Tahara-Hanaoka, S., A. Miyamoto, A. Hara, S.-I. Honda, K. Shibuya, and A. Shibuya. 2005. Identification and characterization of murine DNAM-1 (CD226) and its poliovirus receptor family ligands. Biochem. Biophys. Res. Commun. 329: 996‒1000.
28. Shibuya, K., J. Shirakawa, T. Kameyama, S.-I. Honda, S. Tahara-Hanaoka, A. Miyamoto, M. Onodera, T. Sumida, H. Nakauchi, H. Miyoshi, and A. Shibuya. 2003. CD226 (DNAM-1) Is Involved in Lymphocyte Function‒ associated Antigen 1 Costimulatory Signal for Naive T Cell Differentiation and Proliferation. J. Exp. Med. 198: 1829‒1839.
29. Dardalhon, V., A. S. Schubart, J. Reddy, J. H. Meyers, L. Monney, C. A. Sabatos, R. Ahuja, K. Nguyen, G. J. Freeman, E. A. Greenfield, R. A. Sobel, and V. K. Kuchroo. 2005. CD226 is specifically expressed on the surface of Th1 cells and regulates their expansion and effector functions. J. Immunol. 175: 1558‒1565.
30. Tao, D., L. Shangwu, W. Qun, L. Yan, J. Wei, L. Junyan, G. Feili, J. Boquan, and T. Jinquan. 2005. CD226 Expression Deficiency Causes High Sensitivity to Apoptosis in NK T Cells from Patients with Systemic Lupus Erythematosus. The Journal of Immunology 174: 1281‒1290.
31. Wang, N., H. Yi, L. Fang, J. Jin, Q. Ma, Y. Shen, J. Li, S. Liang, J. Xiong, Z. Li, H. Zeng, F. Jiang, B. Jin, and L. Chen. 2020. CD226 Attenuates Treg Proliferation via Akt and Erk Signaling in an EAE Model. Front. Immunol. 11: 1883.
32. Tagawa, Y., K. Sekikawa, and Y. Iwakura. 1997. Suppression of concanavalin A-induced hepatitis in IFN-gamma(-/-) mice, but not in TNF-alpha(-/-) mice: role for IFN-gamma in activating apoptosis of hepatocytes. J. Immunol. 159: 1418‒1428.
33. Stuart, T., A. Butler, P. Hoffman, C. Hafemeister, E. Papalexi, W. M. Mauck 3rd, Y. Hao, M. Stoeckius, P. Smibert, and R. Satija. 2019. Comprehensive Integration of Single-Cell Data. Cell 177: 1888‒1902.e21.
34. Butler, A., P. Hoffman, P. Smibert, E. Papalexi, and R. Satija. 2018. Integrating single-cell transcriptomic data across different conditions, technologies, and species. Nat. Biotechnol. 36: 411‒420.
35. Nasti, T. H., K. J. Rudemiller, J. B. Cochran, H. K. Kim, Y. Tsuruta, N. S. Fineberg, M. Athar, C. A. Elmets, and L. Timares. 2015. Immunoprevention of chemical carcinogenesis through early recognition of oncogene mutations. J. Immunol. 194: 2683‒2695.
36. Rundhaug, J. E., and S. M. Fischer. 2010. Molecular mechanisms of mouse skin tumor promotion. Cancers 2: 436‒482.
37. Sheppard, S., J. Guedes, A. Mroz, A.-M. Zavitsanou, H. Kudo, S. M. Rothery, P. Angelopoulos, R. Goldin, and N. Guerra. 2017. The immunoreceptor NKG2D promotes tumour growth in a model of hepatocellular carcinoma. Nat. Commun. 8: 13930.
38. Engel, A. M., I. M. Svane, J. Rygaard, and O. Werdelin. 1997. MCA sarcomas induced in scid mice are more immunogenic than MCA sarcomas induced in congenic, immunocompetent mice. Scand. J. Immunol. 45: 463‒470.
39. Boesen, M., I. M. Svane, A. M. Engel, J. Rygaard, A. R. Thomsen, and O. Werdelin. 2000. CD8+ T cells are crucial for the ability of congenic normal mice to reject highly immunogenic sarcomas induced in nude mice with 3- methylcholanthrene. Clin. Exp. Immunol. 121: 210‒215.
40. Muller, A. J., M. D. Sharma, P. R. Chandler, J. B. Duhadaway, M. E. Everhart, B. A. Johnson 3rd, D. J. Kahler, J. Pihkala, A. P. Soler, D. H. Munn, G. C. Prendergast, and A. L. Mellor. 2008. Chronic inflammation that facilitates tumor progression creates local immune suppression by inducing indoleamine 2,3 dioxygenase. Proc. Natl. Acad. Sci. U. S. A. 105: 17073‒ 17078.
41. Swann, J. B., M. D. Vesely, A. Silva, J. Sharkey, S. Akira, R. D. Schreiber, and M. J. Smyth. 2008. Demonstration of inflammation-induced cancer and cancer immunoediting during primary tumorigenesis. Proc. Natl. Acad. Sci. U. S. A. 105: 652‒656.
42. Rothe, M., D. Quarcoo, A. A. Chashchina, S. V. Bozrova, Z. Qin, S. A. Nedospasov, T. Blankenstein, T. Kammertoens, and M. S. Drutskaya. 2013. IL-13 but not IL-4 signaling via IL-4Rα protects mice from papilloma formation during DMBA/TPA two-step skin carcinogenesis. Cancer Med. 2: 815‒825.
43. Zaidi, M. R., and G. Merlino. 2011. The two faces of interferon-γ in cancer. Clin. Cancer Res. 17: 6118‒6124.
44. Mojic, M., K. Takeda, and Y. Hayakawa. 2017. The Dark Side of IFN-γ: Its Role in Promoting Cancer Immunoevasion. Int. J. Mol. Sci. 19.
45. Zaidi, M. R. 2019. The Interferon-Gamma Paradox in Cancer. J. Interferon Cytokine Res. 39: 30‒38.
46. He, Y.-F., X.-H. Wang, G.-M. Zhang, H.-T. Chen, H. Zhang, and Z.-H. Feng. 2005. Sustained low-level expression of interferon-γ promotes tumor development: potential insights in tumor prevention and tumor immunotherapy. Cancer Immunol. Immunother. 54: 891‒897.
47. Zou, Q., J. Jin, Y. Xiao, X. Zhou, H. Hu, X. Cheng, N. Kazimi, S. E. Ullrich, and S.-C. Sun. 2015. T Cell Intrinsic USP15 Deficiency Promotes Excessive IFN-γ Production and an Immunosuppressive Tumor Microenvironment in MCA-Induced Fibrosarcoma. Cell Reports 13: 2470‒2479.